Evaluation of total HCC lifespan , including both clinically evident and pre - clinical development , using combined Network Phenotyping Strategy and Fisher information analysis

We previously showed that for prognostication of hepatocellular cancer (HCC) outcomes, disease parameters need to be considered within a total personal clinical context. This requires preserving the coherence of data values, observed simultaneously for each patient during baseline diagnostic evaluation. Application of Network Phenotyping Strategy provided quantitative descriptors of these patient coherences. Combination of these descriptors with Fisher information about a patient’s tumor mass and the histogram of the tumor masses in the whole cohort, permitted estimation of the time that passed from disease onset until clinical diagnosis (tbaseline). We found faster growth of smaller tumors having total masses <70 (80% of cohort) which involved ~3 times more interacting cellular processes than were observed for slower growing larger tumors (20% of cohort) with total masses >70. Combining the clinical survival and tbaseline normalized all HCC patients to a common 1045 days of mean total disease duration (tbaseline plus post diagnosis survival). We also found a simple relationship between the baseline clinical status, tbaseline and survival. Every difference between a patient baseline clinical profiles and special coherent clinical status (HL1) reduced the above common overall survival by 65 days. In summary, we showed that HCC patients with any given tumor can best have their tumor biology understood, when account is taken of the total clinical and liver context, and with knowing the point in its total history when an HCC diagnosis is made. This ability to compute the tbaseline from standard clinical data brings us closer to calculating survival from diagnosis of individual HCC patients. __________________________________________